.svg)
We’re On a Mission to Modernize Our $19.4B Industry
The Monogram system is changing the way TKAs are done forever. Our precision robotics and FDA-approved, personalized hardware mean patients get a better fit with a faster recovery. With 100,000 TKAs failing each year in a $19.4B market, this is a massive opportunity. Watch the video below or click here to learn more.
Share Price
NASDAQ Here We Come. Meet MGRM.
We’ve reserved the Monogram stock ticker - MGRM - a key step in our journey to going public*. In the meantime, our current private round remains open.
How Our Technology Makes TKAs Better Than Ever
By combining personalized hardware with precision robotics, our clients will have more stable outcomes with a less invasive procedure.
Download Investor Presentation & Company Updates
The First Robot of Its Kind
Our robots create a digital map of each person to make more precise procedures.
In fact, this year we proved our technology worked with a live demonstration in front of a virtual audience of over 5,000 people.
What makes the Monogram robot so effective?
- 7 degrees of freedom to boost range of motion
- Closed loop tracking
- Active navigated milling, a first for a robot in our industry
The World Deserves Personalization
You wouldn’t buy a suit off the rack and expect it to fit your body perfectly. You’d take it to a tailor or have one custom-made. So why would you accept “off the rack” when it comes to a TKA? Patients have been stuck with generic-sized hardware for decades. We fixed it. Our products are optimized for each unique individual. The result is a better fit and less chance of a revision later.
Watch Our Live Demo
We put our revolutionary robotic technology to the test. Watch us perform a LIVE procedure in front of thousands of viewers.
Why Our Solution Is Needed: 100,000 TKAs Fail Each Year.
The result of our system is a better TKA experience across the board. Our robots create highly accurate incisions for our custom hardware. Because of this level of precision, our hardware doesn’t need brittle cement, a relic of the past that is still used in 92% of TKAs.
A Broken Industry
TKAs are done mostly the same today as they were 40 years ago. Practitioners use crude instruments like hand saws and jigs to insert rigid, generic apparatuses. No wonder the results are so bad.
- Over 100,000 TKAs fail each year
- 1/5 of recipients don’t feel better after their procedure.
- Instability, malalignment, and failure of fixation cause 50% of early revisions
Our Market Is Worth $19.4B
By 2027, 50% of all TKA procedures will be robotic, and we aim to have the first active navigated robotic arm on the market. If we are able to succeed we will capture a fraction of this massive market
Company Highlights
Generated Revenue
NSF Grant
Lab
20 Patents
$38M
First
Company
We’re Planning to List on the NASDAQ as MGRM
This is an especially exciting time to invest in Monogram because we intend to list our stock on the NASDAQ this year. This is a rare opportunity to own shares in a company before its planned to trade on an exchange. And once we’re on the exchange our shares will be eligible to be bought by ETFs, mutual funds, institutional investors, and be covered by investment banks.
Download Investor Presentation & Company Updates
.png){kind=logo}
.jpeg){kind=logo}
Meet the Team
Douglas Unis, Md
Benjamin Sexson - CEO
Noel Knape
Kamran Shamaei, PhD
Christopher Scifert, PhD
Kevin Posey
Muhammad Afnan
Sophia Sangiorgio, PhD
Laura Gilmour
Matt DiCicco, M.S.
Dr. Roshan Shah
Robert Jamieson
Dr. Matthew E. Heinrich
Darwin Chen
Dr. Gregory Catlett
FAQs
PUBLIC OFFERING AND LISTING
Please note that SEC Rule 144 mandates that shares purchased under Reg CF (Regulation Crowdfunding) are not eligible for immediate trading and have a 12-month required lock-up period starting from when the investment closed. Equity Stock Transfer has records of when any Reg-CF series-C investments closed.
TRANSFER AGENT
- If you have already paid and registered for Online Access to our shareholder portal, and created your username and password, please skip to step 4.
- To transfer your free trading shares to your broker, you must obtain Online Access here: https://monogram-orthopaedics.equitystock.com/pay and follow the directions. Your DRS (Direct Registration System) transfer agent fees to transfer your shares to your broker are covered when you obtain Online Access.
- After you complete the payment for Online Access, you will receive email instructions on how to register.
- Once you have registered and created your username and password, through the Online Access portal, you will be able to download your Common Stock book-entry statement along with a Welcome Letter on how to initiate the DRS process through your broker.
- Once your broker initiates the DRS process, we will be able to transfer the shares to your brokerage account.
PRIOR INVESTMENTS
GENERAL
FOR FURTHER INFORMATION
This page may include ''forward-looking statements.'' To the extent that the information presented in this presentation discusses financial projections, information, or expectations about Monogram Orthopedics Inc.’s business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' Although Monogram Orthopedics Inc. believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Monogram Orthopedics Inc. does not undertake any duty to update any forward-looking statements except as may be required by law.
The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by Monogram are highly speculative. Investing in shares of Monogram involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.
Monogram intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on Monogram, the offering and any other related topics, please review the Form 1-A offering circular that can be found at the following location EDGAR Entity Landing Page. Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.
DealMaker Securities, LLC is being compensated a 4% commission from the lead Selling Agent engaged by Monogram Orthopaedics Inc. in regards to advertising of this investment. The Company has engaged Digital Offering, LLC (“Digital Offering”) to act as lead selling agent (which we sometimes refer to as the “Selling Agent”) to offer the shares of our common stock, par value $0.001 (the “Common Stock”) to prospective investors in this offering on a “best efforts” basis, which means that there is no guarantee that any minimum amount will be received by the Company in this offering. The Company will pay a cash commission of 7.00% to Digital Offering on sales of the shares of Common Stock. See “Plan of Distribution” in the Offering Circular for details of compensation payable to the Selling Agent in connection with the offering. DealMaker Securities, LLC is not affiliated with other companies mentioned herein.
*NASDAQ Ticker Reservation Tracking #ME9437IN. Our request to reserve the ticker symbol "MGRM" for Monogram Orthopaedics Inc has been approved and will be reserved until 20 September 2024.
Join the Discussion